News

New York has decriminalised the use of marijuana - becoming the 16th US state to do so. The move, which would make possession of a small amount of the drug a violation rather than a felony, was signed into law by governor Andrew Cuomo.

Mark A. R. Kleiman, a prominent drug policy apostate who favored what he viewed as a sensible middle ground on marijuana - eliminate criminal sanctions for selling and using it but preclude full-blown commercial legalization - died on Sunday in Manhattan. He was 68.

Smoking pot cost Kimberly Cue her job. Ms. Cue, a 44-year-old chemical engineer from Silicon Valley, received an offer this year from a medical device manufacturer only to have it rescinded when the company found out that she smoked prescription marijuana to treat post-traumatic stress disorder.

Two major universities are creating the first career paths for young people interested in the business of marijuana.

Opinions

More than half of all Canadians believe drug treatment should focus on abstinence, rather than opioid replacement therapies, according to poll results released this week.

It's becoming increasingly obvious that legalizing marijuana consumption was a colossal public-health blunder.

Drug laws should be designed to minimise damage. This might sound obvious. But the UK's drug laws - along with those of most other countries - arguably do not have this effect. Indeed there is a strong argument that in many respects the blanket prohibition, under criminal statutes, of substances from cannabis to heroin along with the myriad synthetic substances now widely used to mimic their effects, does more harm than good.

The Canadian cannabis industry is booming. From giant industrial operations such as Canopy Growth to smaller "luxury"=9D cannabis retailers, to an array of cannabis "lifestyle"=9D brands and "cannabis brand consultancy"=9D firms, the industry is a lucrative fronti er for those seeking wealth in a rapidly growing market.

Letters

Dear Editor: Contrary to Joe Fries' editorial "Abstinence works best" (Courier, Aug. 16), Rhode Island treats addicted prison inmates with methadone, buprenorphine and naltrexone. Like methadone, buprenorphine is an opioid agonist, or replacement opioid. Naltrexone is an opioid antagonist that blocks opioid receptors.

Re: "Legalizing pot is proving to be a public-health disaster," column, Aug. 11. In his opinion piece on cannabis legalization, Lawrie McFarlane cites a short-term increase in the numbers of adolescents visiting emergency rooms for cannabis in Colorado - a jurisdiction with a commercialized approach to cannabis legalization - as evidence that Canada's much more restrictive public health-oriented approach to legalization has failed.

Re: "Legalizing pot is proving to be a public-health disaster," column, Aug. 11. Lawrie McFarlane's verdict is premature. Legal regulation in Canada isn't analogous to legalization in Colorado, for among other reasons, Colorado allows advertising and initially allowed edibles and extracts with inadequate labelling, packaging and dose limitations.

Alex Berenson's allegation that public support for marijuana law reform is waning ("Marijuana Activists Pass Their High Point," op-ed, June 26) is nothing short of a pipe dream.

Re "Marijuana Damages Young Brains," by Kenneth L. Davis and Mary Jeanne Kreek (Op-Ed, June 17): No one is advocating that young people either consume or have ready access to cannabis. In fact, it is precisely because marijuana use may pose potential risks to certain consumers - for example, adolescents or people with a family history of psychiatric illness - that NORML believes that lawmakers should regulate it accordingly.

To the editor: Your June 28 editorial, "Marijuana-impaired drivers a growing danger," lacks a rational basis for crying wolf. In fact, marijuana consumption's negligible impact on driving ability pales next to alcohol and distraction by smartphone use.

According to Messrs. Kennedy and Sabet, cannabis legalization is "a failed experiment." But in Washington state, which like Colorado legalized in 2012, support has increased from 56% to an astounding 78%. Some failure!